Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate
- 1 May 1994
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 170 (5) , 1556-1561
- https://doi.org/10.1016/s0002-9378(94)05019-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrelActa Obstetricia et Gynecologica Scandinavica, 1992
- Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiolActa Obstetricia et Gynecologica Scandinavica, 1992
- Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agentActa Obstetricia et Gynecologica Scandinavica, 1992
- Comparative contraceptive efficacy and mechanism of action of the norgestimate‐containing triphasic oral contraceptiveActa Obstetricia et Gynecologica Scandinavica, 1992
- Preclinical evaluation of norgestimate, a progestin with minimal androgenic activityAmerican Journal of Obstetrics and Gynecology, 1992
- The metabolic impact of oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 1992
- The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): Results of an open, multicenter study of 59,701 womenAmerican Journal of Obstetrics and Gynecology, 1992
- Supportive European Data on a New Oral Contraceptive Containing NorgestimateActa Obstetricia et Gynecologica Scandinavica, 1990
- Efficacy and Clinical Profile of a New Oral Contraceptive Containing Norgestimate: U.S. Clinical TrialsActa Obstetricia et Gynecologica Scandinavica, 1990
- Oral contraceptives, lipids and cardiovascular diseaseContraception, 1985